Get access
Clinical & Experimental Allergy

The effect of intranasal azelastine, Rhinolast®, on nasal airways obstruction and sneezing following provocation testing with histamine and allergen


Professor R. J. Davies, Department of Respiratory Medicine, St Bartholomew's Hospital, London EC1A 7BE, U.K.


The effect of single dose topical nasal therapy with azelastine hydrochloride (azelastine) on the response of nasal airways resistance (NAR) to provocation testing was studied in 36 patients with seasonal allergic rhinitis. Nasal provocation testing (NPT) with histamine or grass pollen was performed after a single dose of azelastine, 0.28 mg to each nostril, or placebo. NAR was assessed by rhinomanometry for 10 hr following NPT. Compared to placebo the NAR response to histamine was inhibited at both 1 and 2 hr following azelastine administration, significant at 1 hr (P < 0.02) and 2 hr (P < 0.0001). No such effect was observed in relation to allergen-induced changes in NAR. Azelastine also inhibited numbers of sneezes for up to 10 hr following both histamine NPT (P < 0.02) and allergen NPT (P < 0.05), when compared to placebo. Forty-seven per cent of participants experienced bitter or unpleasant taste sensations after azelastine administration but no other unwanted effects were clearly related to azelastine therapy.

Get access to the full text of this article